1.
Vergis J, McCullumsmith RE. Pathway enrichment and FDA-approved drug repurposing analysis for the treatment of CTNNB1 Syndrome modeled in an SH-SY5Y cell line. Translation [Internet]. 2025 Oct. 15 [cited 2025 Nov. 7];14(S1). Available from: https://openjournals.utoledo.edu/index.php/translation/article/view/1507